1. Current treatments miss slowly-dividing cancer cells, risking fatal relapse of childhood brain tumour, SickKids-led study finds

    TORONTO – Aggressive chemotherapy attacking rapidly-dividing cancer cells have greatly improved survival rates for the most common cancerous brain tumour in children; however, nearly 30 per cent of cases result in a fatal recurrence of the tumour. New research led by The Hospital for Sick Children (SickKids) identifies a culprit for relapse in medulloblastoma: a small group of slowly-dividing tumour cells that slide under the radar of traditional therapies.

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes

    1. By dissecting the cellular determinants of tumour growth, we found that different tumour cells have very distinct properties in terms of how quickly they divide and how they respond to therapy.
    2. We predict that the most successful future medulloblastoma therapy will need to target these different cell types in the tumour.
  3. Authors